Randomized trial explores oncological outcomes in patients with ISUP 2 prostate cancer and suspected EPE, indicating heterogeneous risks.
Background International Society of Uro-Pathology (ISUP) grade group 2 prostate cancer (GG2 PCa) with suspicion of extraprostatic extension (EPE) on preoperative multiparametric MRI (mpMRI) presents a paradox: an histologically favorable intermediate-risk tumor with aggressive imaging features. We aimed to characterize this population, and identify predictors of pathological upgrading, downstaging, and oncological outcomes after robot-assisted radical prostatectomy (RARP). Materials and Methods We analyzed data from 150 patients across 8 European centers with MRI-targeted biopsy-confirmed GG2 PCa and mpMRI-suspected EPE (icT3a), stratified by EPE score, who underwent RARP between 2019 and 2024. Primary endpoint was predictors of pathological upgrading (GG ≥ 3); secondary endpoints included downstaging (pT2), surgical margins, and biochemical recurrence (BCR)-free survival. Results Patients were divided by EPE score: low (1–2, n = 87) and high (3, n = 38). Pathological upgrading occurred in 36% (55/150), including 10% to GG 4–5. High EPE score was the only significant predictor. Conversely, 46% (69/150) were downstaged to pT2, with low EPE score as main predictor. Positive surgical margins were observed in 30% (45/150). At a median follow-up of 28 months (IQR 17–43), 5-year BCR-free survival was 67% (95% CI 53–85). Posterior/apical EPE on MRI and cT3a stage were linked to higher BCR risk. Conclusions GG2 PCa with mpMRI-suspected EPE is heterogeneous, showing risks of both upgrading and organ-confined disease. EPE score was the main predictor of both. Despite imaging suspicion, RARP outcomes remained favorable.
No takes yet. Share an insight, caveat, or question.
Brek et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: